Company Profile

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Employees

154

Sector

Biotechnology & Medical Research

More about the company

07/22/07	MorphoSys Out Licenses Pre-Clinical Oncology Program	CI
17/21/17	MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	MT
15/21/15	Constellation Announces Management Changes	CI
15/21/15	Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	CI
15/21/15	Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	CI
15/21/15	DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	MT
15/21/15	MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	MT
15/21/15	MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	MT
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	CI
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	CI
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	CI
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	CI
15/21/15	MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	CI

17/21/17	CONSTELLATION PHARMACEUTICALS : RBC Capital Downgrades Constellation Pharmaceuticals to Sector Perform From Outperform, Price Target Cut to $34 From $50	MT
04/21/04	CONSTELLATION PHARMACEUTICALS : Jefferies Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts Price Target to $34 From $53	MT
03/21/03	CONSTELLATION PHARMACEUTICALS : Truist Securities Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts PT to $34 From $50	MT
03/21/03	CONSTELLATION PHARMACEUTICALS : BMO Capital Downgrades Constellation Pharmaceuticals to Market Perform from Outperform, Adjusts Price Target to $34 from $48	MT
03/21/03	CONSTELLATION PHARMACEUTICALS : JPMorgan Downgrades Constellation Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $34 from $38	MT

19/21/19	Royalty Pharma : MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma	AQ
17/21/17	MorphoSys AG :	AQ
15/21/15	Constellation Pharmaceuticals : Completion of Acquisition or Disposition of Assets (Form 8-K)	PU
15/21/15	CONSTELLATION PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
14/21/14	Constellation Pharmaceuticals : Provides an Update from the Ongoing MANIFEST Study of Pelabresib	AQ

29/21/29	Morphosys macht mehr Umsatz - Operativer Verlust höher
29/21/29	Morphosys verbucht in 2Q dank Finanzerträgen Gewinn
27/21/27	AKTIE IM FOKUS 2: MorphoSys setzen Talfahrt fort - Commerzbank streicht 'Buy'
26/21/26	MÄRKTE EUROPA/Etwas leichter - Bitcoin mit Rally
26/21/26	XETRA-SCHLUSS/Leichte Abgaben zu Wochenbeginn - Morphosys brechen ein

Manager	Title	Age	Since
John McKenna PSD	President	-	-
Kia Khalaghpour IRC	Investor Relations Contact	-	-
Irina Apostolou PRN	Corporate Officer/Principal	-	01/08/2016

Constellation Pharmaceuticals, Inc. Share Price

Stocks

CNST

US2103731061

Biotechnology & Medical Research

Latest news : Constellation Pharmaceuticals, Inc.

Analysts' recommendations: Constellation Pharmaceuticals, Inc.

Press Releases: Constellation Pharmaceuticals, Inc.

News in other languages: Constellation Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Constellation Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Kathleen Warnecke BRD	Director/Board Member	-	15/07/2021
John McKenna BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/21/15	Jeffrey Humphrey	Issuer sale	Chief Technology Officer	1,68,055	0.3504%
15/21/15	Emma Reeve	Issuer sale	Chief Financial Officer	3,48,319	0.7262%
15/21/15	Karen Valentine	Issuer sale	General Counsel	2,04,764	0.4269%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONSTELLATION PHARMACEUTICALS, INC.	+0.06%	+0.12%	-	-	162.47Cr
ARGENX SE	+3.98%	+5.55%	+76.40%	+136.18%	5.62TCr
WUXI APPTEC CO., LTD.	-3.12%	+5.11%	+71.57%	+94.67%	5.54TCr
BIONTECH SE	+3.01%	+7.73%	-10.44%	-10.07%	2.38TCr
INSMED INCORPORATED	+2.03%	+4.60%	+11.24%	+426.65%	2.32TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.64%	+10.54%	+39.81%	-4.50%	1.81TCr
GENMAB A/S	+4.11%	+8.89%	+44.60%	-27.73%	1.68TCr
PHARMAESSENTIA CORPORATION	+2.57%	+20.26%	+181.98%	+355.99%	1.59TCr
EXELIXIS, INC.	+1.93%	+3.17%	+23.97%	+187.09%	1.36TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.20%	+10.70%	+42.91%	-	1.3TCr
Average	+2.53%	+7.25%	+53.56%	+144.78%	2.62TCr
Weighted average by Cap.	+1.95%	+6.09%	+57.27%	+135.41%